AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27941492 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sets of 10 repetitions
Number of subjects: 19
Study 27941492 — intervention group
Group type: COMPARATOR
Intervention: 5 sets of 10 repetitions
Number of subjects: 19
Study 26446416 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 130
Study 26446416 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 130
Study 23289728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 208
Study 23289728 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 208
Study 23289728 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline AGEs levels
Number of subjects: 208
Study 23289728 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels
Number of subjects: 208
Study 21842188 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory bulb volume measurements and olfactory function tests (odor threshold, odor discrimination, odor identification)
Number of subjects: 87
Study 17947301 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy
Number of subjects: 0
Study 17947301 — intervention group
Group type: COMPARATOR
Intervention: Initial monotherapy
Number of subjects: 0
Study 17947301 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment strategy (without treatment adjustments)
Number of subjects: 0
Study 17048425 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 276
Study 17048425 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 276
Study 17048425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 276
Study 12952249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 24
Study 12952249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11129008 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day course of oral prednisolone (10 mg/day for ages 5-11, 0.5 mg/kg for ages 12 and older)
Number of subjects: 50
Study 11129008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9044556 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (single dose)
Number of subjects: 51
Study 9044556 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (repetitive doses)
Number of subjects: 51
Study 9044556 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg ondansetron (single dose)
Number of subjects: 51
Study 9044556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 51
Study 1576067 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg as a single dose
Number of subjects: 8
Study 1576067 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg four times daily for 8 days
Number of subjects: 8
Study 1576067 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 50 mg four times daily for 27 days
Number of subjects: 8
Study 1576067 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen administration
Number of subjects: 8
Study 28574182 — intervention group
Group type: COMPARATOR
Intervention: Standard bolus
Number of subjects: 19
Study 28574182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination bolus 70/30
Number of subjects: 19
Study 28574182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination bolus 60/40
Number of subjects: 19
Study 28574182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination bolus 30/70
Number of subjects: 19
Study 26223246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Number of subjects: 150
Study 26223246 — intervention group
Group type: COMPARATOR
Intervention: Comparison Health and Wellness (control)
Number of subjects: 150
Study 23111004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) hypocaloric diet
Number of subjects: 40
Study 23111004 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) hypocaloric diet
Number of subjects: 40
Study 21968663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole nitrate 2% cream, once daily for four weeks
Number of subjects: 32
Study 19765006 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with docosahexaenoic acid and arachidonic acid (LCPUFA)
Number of subjects: 229
Study 19765006 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 229
Study 16456211 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions promoting evidence-based supply of non-prescription medicines
Number of subjects: 60
Study 15275801 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral parecoxib sodium followed by oral valdecoxib
Number of subjects: 191
Study 15275801 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 191
Study 11439738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate conductivity adjusted to be 0.3 mS/cm more than the mean during the run-in period (B)
Number of subjects: 0
Study 11439738 — intervention group
Group type: COMPARATOR
Intervention: Dialysate conductivity adjusted to be 0.3 mS/cm less than the mean during the run-in period (C)
Number of subjects: 0
Study 11439738 — intervention group
Group type: COMPARATOR
Intervention: Standard PFD treatment (A)
Number of subjects: 0
Study 9215016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg h-1
Number of subjects: 55
Study 9215016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 mg h-1
Number of subjects: 55
Study 9215016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 1 mg h-1 combined with morphine 8 micrograms h-1
Number of subjects: 55
Study 9215016 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study 7955969 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 507
Study 2890709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular (ICV) cholinergic drug infusion
Number of subjects: 0
Study 2890709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30127137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 100
Study 30127137 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 100
Study 27505702 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation intervention
Number of subjects: 1302
Study 24456988 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended iterative reconstruction (iDOSE 1‐4)
Number of subjects: 44
Study 24456988 — intervention group
Group type: COMPARATOR
Intervention: Filtered back projection
Number of subjects: 44
Study 24456988 — intervention group
Group type: EXPERIMENTAL
Intervention: iDOSE levels (1-4)
Number of subjects: 44
Study 21848545 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable dental prostheses (RDP)
Number of subjects: 307
Study 21848545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dental prostheses (FDP)
Number of subjects: 307
Study 21848545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dental treatment)
Number of subjects: 307
Study 20398111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone-emitting otoscope
Number of subjects: 2305
Study 20398111 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire about hearing handicap
Number of subjects: 2305
Study 20398111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both tools
Number of subjects: 2305
Study 20398111 — intervention group
Group type: COMPARATOR
Intervention: No screening (Control)
Number of subjects: 2305
Study 18466043 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3, 6, 9, 12, or 15 mg daily)
Number of subjects: 1326
Study 18466043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study 15665343 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine eye drops (once daily for 2 years)
Number of subjects: 105
Study 15665343 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops (once daily for 2 years)
Number of subjects: 105
Study 12947054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8, every 3 weeks for six cycles (CG)
Number of subjects: 557
Study 12947054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8, every 3 weeks for six cycles (CGV)
Number of subjects: 557
Study 12947054 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8, every 3 weeks for three cycles, followed by vinorelbine 30 mg/m2 days 1 and 8 plus ifosfamide 3 g/m2 day 1, every 3 weeks for three cycles (GV-VI)
Number of subjects: 557
Study 12947054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8 (CG)
Number of subjects: 557
Study 12947054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8 (CGV)
Number of subjects: 557
Study 12947054 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1,000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8 (GV-VI)
Number of subjects: 557
Study 10446879 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant non-Hodgkin's lymphoma (MNHL) patients
Number of subjects: 33
Study 8690822 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 0
Study 8690822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 0
Study 6646956 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional bias in visual perception tasks (dot-asynchrony judgments and letter recall)
Number of subjects: 65
Study 31474396 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise program
Number of subjects: 108
Study 31474396 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 108
Study 28834836 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment group (n = 40)
Number of subjects: 72
Study 28834836 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment group (n = 32)
Number of subjects: 72
Study 25714415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injection plus physiotherapy (INJPT)
Number of subjects: 0
Study 25714415 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 0
Study 23315603 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured behavioral group
Number of subjects: 71
Study 23315603 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 71
Study 23315603 — intervention group
Group type: COMPARATOR
Intervention: One-to-one education
Number of subjects: 71
Study 23315603 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger behavioral group
Number of subjects: 71
Study 23315603 — intervention group
Group type: COMPARATOR
Intervention: Younger control group
Number of subjects: 71
Study 23315603 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care interventions
Number of subjects: 71
Study 22082443 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 iu hCG and a single dose of 50 mg dexamethasone
Number of subjects: 152
Study 22082443 — intervention group
Group type: COMPARATOR
Intervention: Control group (110 cycles without treatment)
Number of subjects: 152
Study 19012048 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum oleous nasal spray, 4 microg/puff, three times a day for 3 consecutive days
Number of subjects: 208
Study 19012048 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsicum oleous nasal spray (1 microg/puff and 2 microg/puff)
Number of subjects: 208
Study 19012048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 17448621 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-based patient education (group A)
Number of subjects: 113
Study 17448621 — intervention group
Group type: COMPARATOR
Intervention: Computer-based patient education (group B)
Number of subjects: 113
Study 12644418 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction and halothane/nitrous oxide maintenance
Number of subjects: 322
Study 12644418 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide
Number of subjects: 322
Study 11062569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic outrigger splint
Number of subjects: 100
Study 11062569 — intervention group
Group type: COMPARATOR
Intervention: Palmar blocking splint
Number of subjects: 100
Study 9059063 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission induction therapy (AVC) with terarubicin (THP‐ADR), vincristine, and continuous infusion of cytosine arabinoside (Ara C) for 32 or 48 weeks.
Number of subjects: 45
Study 9059063 — intervention group
Group type: EXPERIMENTAL
Intervention: VP16 + high dose Ara C used sequentially for 32 or 48 weeks.
Number of subjects: 45
Study 9059063 — intervention group
Group type: COMPARATOR
Intervention: Treatment period of 32 weeks vs 48 weeks.
Number of subjects: 45
Study 9059063 — intervention group
Group type: EXPERIMENTAL
Intervention: ANLL‐9205 protocol.
Number of subjects: 45
Study 8458096 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard GH treatment (20 units/m2/week)
Number of subjects: 29
Study 8458096 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH treatment (40 units/m2/week)
Number of subjects: 29
Study 8458096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 29
Study 8458096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GH treatment groups
Number of subjects: 29
Study 3724995 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term lithium treatment
Number of subjects: 16
Study 3724995 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (6 weeks)
Number of subjects: 16
Study 3724995 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinstituted lithium treatment (6 weeks)
Number of subjects: 16
Study 3724995 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lithium medication (replication study)
Number of subjects: 16
Study 30836801 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 10 mg twice weekly
Number of subjects: 0
Study 30836801 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg twice weekly
Number of subjects: 0
Study 30836801 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 29139599 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall-prevention program
Number of subjects: 85
Study 29139599 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Attitudes to Falls-Related Interventions Scale (AFRIS) scores
Number of subjects: 85
Study 26294761 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Pink eye' label
Number of subjects: 0
Study 26294761 — intervention group
Group type: COMPARATOR
Intervention: 'Eye infection' label
Number of subjects: 0
Study 24170757 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-titration of bolus insulin glulisine
Number of subjects: 0
Study 24170757 — intervention group
Group type: COMPARATOR
Intervention: Physician titration of bolus insulin glulisine
Number of subjects: 0
Study 22436405 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls-related self-efficacy assessed by the activities-specific balance confidence (ABC) scale
Number of subjects: 79
Study 20137090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood glucose control using insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l.
Number of subjects: 1000
Study 20137090 — intervention group
Group type: COMPARATOR
Intervention: Standard current approach to blood glucose management (Control group).
Number of subjects: 1000
Study 20137090 — intervention group
Group type: COMPARATOR
Intervention: Tight blood glucose control (I) and Standard current approach (C).
Number of subjects: 1000
Study 20137090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood glucose control (I).
Number of subjects: 1000
Study 18393319 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg/kg rFVIIa (200 + 4x 100 microg/kg)
Number of subjects: 256
Study 18393319 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg/kg rFVIIa (200 + 100 microg/kg)
Number of subjects: 256
Study 18393319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 15809563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up style ankle support
Number of subjects: 93
Study 15809563 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive tape and semirigid style ankle support
Number of subjects: 93
Study 15809563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ankle support)
Number of subjects: 93
Study 12088969 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 60
Study 12088969 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine
Number of subjects: 60
Study 12088969 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bupivacaine and ropivacaine
Number of subjects: 60
Study 10754428 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 15
Study 10754428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8701046 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 0
Study 1887746 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (120 micrograms)
Number of subjects: 15
Study 1887746 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (50 micrograms)
Number of subjects: 15
Study 1887746 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (720 micrograms)
Number of subjects: 15
Study 1887746 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (300 micrograms)
Number of subjects: 15
Study 1887746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7167734 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/day of trimipramine
Number of subjects: 62
Study 7167734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion (135 women)
Number of subjects: 405
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous Caesarean section
Number of subjects: 405
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior placenta praevia
Number of subjects: 405
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Major placenta praevia
Number of subjects: 405
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative bleeding of more than 250 mL
Number of subjects: 405
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 405
Study 30854569 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Caesarean section
Number of subjects: 405
Study 27756097 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple emulsion (ME1) containing Ascorbyl Palmitate (AP) and Sodium Ascorbyl Phosphate (SAP)
Number of subjects: 11
Study 27756097 — intervention group
Group type: COMPARATOR
Intervention: Control (without AP and SAP)
Number of subjects: 11
Study 26764966 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + bioactive glass putty
Number of subjects: 10
Study 26764966 — intervention group
Group type: COMPARATOR
Intervention: CAF alone
Number of subjects: 10
Study 23185084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 4 x 4 minutes at 85-95% of peak heart rate, three times per week for eight weeks, repeated three times throughout one year
Number of subjects: 52
Study 23185084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 23185084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 52
Study 22847212 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF experienced (EXP)
Number of subjects: 300
Study 22847212 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF naïve (NAÏVE)
Number of subjects: 300
Study 20682154 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (n = 35)
Number of subjects: 68
Study 20682154 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (n = 33)
Number of subjects: 68
Study 17548727 — intervention group
Group type: COMPARATOR
Intervention: Noncotinine group (nondetectable cotinine)
Number of subjects: 402
Study 17548727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cotinine group (cotinine between 0.2 and 1.6 ng/mL)
Number of subjects: 402
Study 17548727 — intervention group
Group type: EXPERIMENTAL
Intervention: Top decile cotinine group (cotinine ≥ 1.7 ng/mL)
Number of subjects: 402
Study 15602499 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg gaboxadol hydrochloride
Number of subjects: 10
Study 15602499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11966623 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (81 mg) of intravesical bacille Calmette-Guérin (BCG)
Number of subjects: 500
Study 11966623 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose (27 mg) of intravesical bacille Calmette-Guérin (BCG)
Number of subjects: 500
Study 9818881 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral branched-chain amino acids (BCAAs) at a dosage of 77 mg/kg
Number of subjects: 6
Study 9818881 — intervention group
Group type: COMPARATOR
Intervention: Control noncaloric beverage
Number of subjects: 6
Study 7536208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas alone
Number of subjects: 61
Study 7536208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas plus insulin
Number of subjects: 61
Study 7536208 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily insulin
Number of subjects: 61
Study 7536208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 61
Study 7536208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy
Number of subjects: 61
Study 7536208 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 61